LTI0

Research LTI0 on Bullrun: market cap EUR 3.47M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerLTI0
• ExchangeF
• CountryCanada
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 3.47M
• Financial periodQ4 2025
• Net income-EUR 7.76M
• Free cash flow-EUR 5.84M

Valuation Snapshot

latest market cap is EUR 3.47M.

About LTI0

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes.

Frequently asked questions

What is LTI0's market cap?

LTI0's market capitalization is EUR 3.47M.

What does LTI0 do?

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States.